Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Incidence and risk factors for new-onset diabetes in HIV-infected patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.

De Wit S, Sabin CA, Weber R, Worm SW, Reiss P, Cazanave C, El-Sadr W, Monforte Ad, Fontas E, Law MG, Friis-Møller N, Phillips A; Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.

Diabetes Care. 2008 Jun;31(6):1224-9. doi: 10.2337/dc07-2013. Epub 2008 Feb 11.

2.

Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment.

Capeau J, Bouteloup V, Katlama C, Bastard JP, Guiyedi V, Salmon-Ceron D, Protopopescu C, Leport C, Raffi F, Chêne G; ANRS CO8 APROCO-COPILOTE Cohort Study Group.

AIDS. 2012 Jan 28;26(3):303-14. doi: 10.1097/QAD.0b013e32834e8776.

PMID:
22089377
3.

Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study.

Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, Bruyand M, Reiss P, El-Sadr W, Monforte AD, Friis-Møller N, Lundgren JD, Law MG; D:A:D Study Group.

J Int AIDS Soc. 2012 Oct 10;15(2):17426. doi: 10.7448/IAS.15.2.17426.

4.

Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretroviral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study.

Worm SW, Sabin C, Weber R, Reiss P, El-Sadr W, Dabis F, De Wit S, Law M, Monforte AD, Friis-Møller N, Kirk O, Fontas E, Weller I, Phillips A, Lundgren J.

J Infect Dis. 2010 Feb 1;201(3):318-30. doi: 10.1086/649897.

5.

Risk factors for incident diabetes mellitus among HIV-infected patients receiving combination antiretroviral therapy in Taiwan: a case-control study.

Lo YC, Chen MY, Sheng WH, Hsieh SM, Sun HY, Liu WC, Wu PY, Wu CH, Hung CC, Chang SC.

HIV Med. 2009 May;10(5):302-9. doi: 10.1111/j.1468-1293.2008.00687.x. Epub 2009 Feb 8.

6.

Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy.

Kowalska JD, Reekie J, Mocroft A, Reiss P, Ledergerber B, Gatell J, d'Arminio Monforte A, Phillips A, Lundgren JD, Kirk O; EuroSIDA study group.

AIDS. 2012 Jan 28;26(3):315-23. doi: 10.1097/QAD.0b013e32834e8805.

PMID:
22112597
7.

Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.

Bussmann H, Wester CW, Thomas A, Novitsky V, Okezie R, Muzenda T, Gaolathe T, Ndwapi N, Mawoko N, Widenfelt E, Moyo S, Musonda R, Mine M, Makhema J, Moffat H, Essex M, Degruttola V, Marlink RG.

J Acquir Immune Defic Syndr. 2009 May 1;51(1):37-46. doi: 10.1097/QAI.0b013e31819ff102.

8.

Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study.

Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L; D:A:D study group; Royal Free Hospital Clinic Cohort; INSIGHT study group; SMART study group; ESPRIT study group.

PLoS Med. 2015 Mar 31;12(3):e1001809. doi: 10.1371/journal.pmed.1001809. eCollection 2015 Mar.

9.
10.

The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study.

Law MG, Friis-Møller N, El-Sadr WM, Weber R, Reiss P, D'Arminio Monforte A, Thiébaut R, Morfeldt L, De Wit S, Pradier C, Calvo G, Kirk O, Sabin CA, Phillips AN, Lundgren JD; D:A:D Study Group.

HIV Med. 2006 May;7(4):218-30.

11.

Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.

Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, Akerlund B, Calvo G, Monforte Ad, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD.

Arch Intern Med. 2006 Aug 14-28;166(15):1632-41.

PMID:
16908797
12.

Incidence of diabetes mellitus in a population-based cohort of HIV-infected and non-HIV-infected persons: the impact of clinical and therapeutic factors over time.

Tripathi A, Liese AD, Jerrell JM, Zhang J, Rizvi AA, Albrecht H, Duffus WA.

Diabet Med. 2014 Oct;31(10):1185-93. doi: 10.1111/dme.12455. Epub 2014 Apr 28.

PMID:
24673640
13.

Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study.

Worm SW, Sabin CA, Reiss P, El-Sadr W, Monforte Ad, Pradier C, Thiebaut R, Law M, Rickenbach M, De Wit S, Lundgren JD, Friis-Møller N.

Diabetes Care. 2009 Mar;32(3):474-80. doi: 10.2337/dc08-1394. Epub 2008 Dec 3.

14.
15.

Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study.

Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group, Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Karafoulidou A, Miro JM, Lundgren J, Chene G, Egger M.

Antivir Ther. 2009;14(8):1065-74. doi: 10.3851/IMP1462.

16.

New-Onset Diabetes and Antiretroviral Treatments in HIV-Infected Adults in Thailand.

Riyaten P, Salvadori N, Traisathit P, Ngo-Giang-Huong N, Cressey TR, Leenasirimakul P, Techapornroong M, Bowonwatanuwong C, Kantipong P, Nilmanat A, Yutthakasemsunt N, Chutanunta A, Thongpaen S, Klinbuayaem V, Decker L, Le Cœur S, Lallemant M, Capeau J, Mary JY, Jourdain G.

J Acquir Immune Defic Syndr. 2015 Aug 1;69(4):453-9. doi: 10.1097/QAI.0000000000000647.

PMID:
25886928
17.

Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction.

Data Collection on Adverse Events of Anti-HIV Drugs Study Group, Sabin CA, d'Arminio Monforte A, Friis-Moller N, Weber R, El-Sadr WM, Reiss P, Kirk O, Mercie P, Law MG, De Wit S, Pradier C, Phillips AN, Lundgren JD.

Clin Infect Dis. 2008 Apr 1;46(7):1101-10. doi: 10.1086/528862.

18.

Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV Cohort Study.

Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B, Cavassini M, Bernasconi E, Schmid P, Egger M, Weber R; Swiss HIV Cohort Study.

Clin Infect Dis. 2007 Jul 1;45(1):111-9. Epub 2007 May 21.

19.

Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study.

Guiguet M, Boué F, Cadranel J, Lang JM, Rosenthal E, Costagliola D; Clinical Epidemiology Group of the FHDH-ANRS CO4 cohort.

Lancet Oncol. 2009 Dec;10(12):1152-9. doi: 10.1016/S1470-2045(09)70282-7. Epub 2009 Oct 7.

PMID:
19818686
20.

Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?

Mocroft A, Rockstroh J, Soriano V, Ledergerber B, Kirk O, Vinogradova E, Reiss P, Katlama C, Phillips AN, Lundgren JD; EuroSIDA Study Group.

Antivir Ther. 2005;10(7):779-90.

PMID:
16312175
Items per page

Supplemental Content

Write to the Help Desk